Phase I Open Label Study of AS1411 in Advanced Solid Tumours

Inclusion Criteria:

- Patients with advanced solid tumours that were refractory to conventional/standard
treatment

- Age >/ 18 years

- ECOG performance status /60%

- Life expectancy >/ 8 weeks

- Adequate organ and marrow function

Exclusion Criteria:

- Radiotherapy or chemotherapy in the 4 weeks before study entry (6 weeks for
nitrosourea or mitomycin C

- Lack of recovery from adverse events (AEs) caused by agents administered before study
entry; current use of other investigational agent(s)

- Uncontrolled brain metastases including a need for corticosteroid therapy

- Pregnancy

- Uncontrolled intercurrent illness

- Psychiatric illness/social situations that could limit compliance